Last $12.81 USD
Change Today -0.275 / -2.10%
Volume 7.0K
IPSEY On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
OTC US
Stuttgart
As of 1:50 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

ipsen sa-sponsored adr (IPSEY) Snapshot

Open
$12.92
Previous Close
$13.08
Day High
$12.92
Day Low
$12.75
52 Week High
11/19/14 - $13.11
52 Week Low
04/11/14 - $9.91
Market Cap
4.2B
Average Volume 10 Days
9.2K
EPS TTM
--
Shares Outstanding
331.1M
EX-Date
06/4/14
P/E TM
--
Dividend
$0.27
Dividend Yield
2.12%
Current Stock Chart for IPSEN SA-SPONSORED ADR (IPSEY)

Related News

No related news articles were found.

ipsen sa-sponsored adr (IPSEY) Related Businessweek News

View More BusinessWeek News

ipsen sa-sponsored adr (IPSEY) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,602 Employees
Last Reported Date: 03/26/14
Founded in 1929

ipsen sa-sponsored adr (IPSEY) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.4M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

ipsen sa-sponsored adr (IPSEY) Key Developments

Ipsen S.A. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 03:40 PM

Ipsen S.A. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 03:40 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Ipsen and Salk Institute Continue Joint Medical Science Research

Ipsen SA and Salk Institute for Biological Studies announced renewal of their collaboration in medical sciences for another three years. Ipsen and the Salk Institute target to achieve critical insights in the understanding of human diseases so as to develop new therapies for the treatment of patients afflicted with serious medical conditions. Over the next three years Salk Institute scientists will carry out research under the renewed Salk-Ipsen Life Sciences Program. Collaboration in the past three years led to deeper knowledge of how modified viruses can induce laboratory tumour models to better understand human cancer, how human induced pluripotent stem cell neurons may be used to study neurodegenerative diseases, and how tumour cells interact with their tissue microenvironment. The continuing research on these programmes is expected to provide further insights and progress in the development of therapeutics in the fields of oncology, endocrinology and neurodegenerative diseases.

Otonomy Enters into Licensing Pact with Ipsen

Otonomy and Ipsen announced that they have entered into an exclusive licensing agreement enabling Otonomy to utilize Ipsen's gacyclidine data in the development and registration of OTO-311. OTO-311 is Otonomy's sustained-exposure formulation of gacyclidine, an N-Methyl-D-Aspartate receptor antagonist, in development for the treatment of tinnitus.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPSEY:US $12.81 USD -0.275

IPSEY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €13.19 EUR +0.22
Meda AB kr104.80 SEK +1.20
Orion Oyj €28.07 EUR +0.44
Procter & Gamble Hygiene & Health Care Ltd 5,625 INR -140.45
Recordati SpA €13.83 EUR -0.05
View Industry Companies
 

Industry Analysis

IPSEY

Industry Average

Valuation IPSEY Industry Range
Price/Earnings 20.4x
Price/Sales 2.5x
Price/Book 3.2x
Price/Cash Flow 19.4x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN SA-SPONSORED ADR, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.